Endophenotypes and biological markers of schizophrenia: From biological signs of illness to novel treatment targets

Current Pharmaceutical Design

Volumn 19, Issue 36, 2013, Pages 6462-6479

  Ferrarelli, Fabio ^a,b,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Biomarkers; Endophenotypes; Schizophrenia; Treatment targets

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; AMPA RECEPTOR; ATOMOXETINE; BIOLOGICAL MARKER; BITOPERTIN; BL 1020; CALCINEURIN; CATECHOL METHYLTRANSFERASE; CHLORPROMAZINE; CYCLOSERINE; DEXTRO ALANINE; DEXTRO SERINE; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; DOPAMINE; GLUTAMIC ACID; GLYCINE; KETAMINE; N ACETYLASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; NICOTINIC AGENT; NORADRENALIN; PERPHENAZINE; PLACEBO; RACLOPRIDE C 11; SARCOSINE; UNCLASSIFIED DRUG; XANOMELINE;

ALCOHOLISM; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BOLD SIGNAL; BRAIN ELECTROPHYSIOLOGY; BRAIN SIZE; BRAIN VENTRICLE; CENTRAL NERVOUS SYSTEM; CHOLINERGIC TRANSMISSION; COGNITION; DECLARATIVE MEMORY; DEFAULT MODE NETWORK; DOPAMINERGIC ACTIVITY; ELECTROENCEPHALOGRAM; ENDOPHENOTYPE; EVENT RELATED POTENTIAL; EVOKED RESPONSE; FAMILY HISTORY; FIRST DEGREE RELATIVE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GENETIC ASSOCIATION; GRAY MATTER; HUMAN; LEARNING; MAJOR DEPRESSION; MEMORY DISORDER; MISMATCH NEGATIVITY; NAUSEA AND VOMITING; NEGATIVE SYNDROME; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OSCILLATION; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PREPULSE INHIBITION; PRIORITY JOURNAL; REVIEW; SACCADIC EYE MOVEMENT; SCHIZOPHRENIA; SENSORY GATING; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP SPINDLE; SMOOTH PURSUIT EYE MOVEMENT; TEMPORAL LOBE; TRANSCRANIAL MAGNETIC STIMULATION; VERBAL MEMORY; WHITE MATTER; WORKING MEMORY;

ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; ENDOPHENOTYPES; HUMANS; SCHIZOPHRENIA;

EID: 84885449153     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990554     Document Type: Review

References (216)

1. Nicholl D, Akhras KS, Diels J, Schadrack J. Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective. Curr Med Res Opin 2010; 26: 943-55.
2. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602.
3. American Psychiatric Association., American Psychiatric Association. Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. American Psychiatric Association: Washington, DC 2000.
4. Matheson SL, Shepherd AM, Laurens KR, Carr VJ. A systematic meta-review grading the evidence for non-genetic risk factors and putative antecedents of schizophrenia. Schizophr Res 2011; 133: 133-42.
5. Abbott A. Schizophrenia: The drug deadlock. Nature 2010; 468: 158-9.
6. Heckers S. Bleuler and the neurobiology of schizophrenia. Schizophr Bull 2011; 37: 1131-5.
7. Gottesman, II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160: 636-45.
8. Braff DL, Freedman R, Schork NJ, Gottesman, II. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr Bull 2007; 33: 21-32.
9. Cohen J. Statistical Power Ananlysis for the Behavioral Sciences. Erlbaum: Hillsdale, NJ 1988.
10. Chen Y, Bidwell LC, Norton D. Trait vs. State Markers for Schizophrenia: Identification and Characterization through Visual Processes. Curr Psychiatry Rev 2006; 2: 431-8.
11. Erlenmeyer-Kimling L. Neurobehavioral deficits in offspring of schizophrenic parents: liability indicators and predictors of illness. Am J Med Genet 2000; 97: 65-71.
12. Smieskova R, Fusar-Poli P, Allen P, et al. Neuroimaging predictors of transition to psychosis--a systematic review and meta-analysis. Neurosci Biobehav Rev 2010; 34: 1207-22.
13. Thaker GK. Schizophrenia endophenotypes as treatment targets. Expert Opin Ther Targets 2007; 11: 1189-206.
14. Karam CS, Ballon JS, Bivens NM, et al. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol Sci 2010; 31: 381-90.
15. Lindstrom LH, Gefvert O, Hagberg G, et al. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry 1999; 46: 681-8.
16. McGowan S, Lawrence AD, Sales T, Quested D, Grasby P. Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch Gen Psychiatry 2004; 61: 134-42.
17. Laruelle M, Abi-Dargham A, van Dyck C, et al. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biol Psychiatry 2000; 47: 371-9.
18. Abi-Dargham A, Rodenhiser J, Printz D, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000; 97: 8104-9.
19. Howes OD, Montgomery AJ, Asselin MC, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 2009; 66: 13-20.
20. Abi-Dargham A, Mawlawi O, Lombardo I, et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 2002; 22: 3708-19.
21. Abi-Dargham A, Xu X, Thompson JL, et al. Increased prefrontal cortical D1 receptors in drug naive patients with schizophrenia: a PET study with [11C]NNC112. J Psychopharmacol 2011.
22. Laruelle M, Abi-Dargham A, van Dyck CH, et al. Single photon emission computerized tomography imaging of amphetamineinduced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996; 93: 9235-40.
23. Breier A, Su TP, Saunders R, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997; 94: 2569-74.
24. Stober G, Ben-Shachar D, Cardon M, et al. Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry 2009; 10: 127-55.
25. Howes OD, Kambeitz J, Kim E, et al. The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment: Meta-analysis of Imaging Studies. Arch Gen Psychiatry 2012.
26. Fusar-Poli P, Meyer-Lindenberg A. Striatal Presynaptic Dopamine in Schizophrenia, Part II: Meta-Analysis of [18F/11C]-DOPA PET Studies. Schizophr Bull 2012.
27. Karlsson P, Farde L, Halldin C, Sedvall G. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 2002; 159: 761-7.
28. Nieratschker V, Nothen MM, Rietschel M. New Genetic Findings in Schizophrenia: Is there Still Room for the Dopamine Hypothesis of Schizophrenia? Front Behav Neurosci 2010; 4: 23.
29. Ibrahim HM, Hogg AJ, Jr., Healy DJ, Haroutunian V, Davis KL, Meador-Woodruff JH. Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry 2000; 157: 1811-23.
30. Eastwood SL, McDonald B, Burnet PW, Beckwith JP, Kerwin RW, Harrison PJ. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Brain Res Mol Brain Res 1995; 29: 211-23.
31. Porter RH, Eastwood SL, Harrison PJ. Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Res 1997; 751: 217-31.
32. Maddock RJ, Buonocore MH. MR Spectroscopic Studies of the Brain in Psychiatric Disorders. Curr Top Behav Neurosci 2012.
33. Egerton A, Fusar-Poli P, Stone JM. Glutamate and psychosis risk. Curr Pharm Des 2012; 18: 466-78.
34. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM. NAcetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 2007; 81: 89-131.
35. Steen RG, Hamer RM, Lieberman JA. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 2005; 30: 1949-62.
36. Brugger S, Davis JM, Leucht S, Stone JM. Proton magnetic resonance spectroscopy and illness stage in schizophrenia--a systematic review and meta-analysis. Biol Psychiatry 2011; 69: 495-503.
37. Marenco S, Bertolino A, Weinberger DR. In vivo NMR measures of NAA and the neurobiology of schizophrenia. Adv Exp Med Biol 2006; 576: 227-40; discussion 361-3.
38. Curley AA, Lewis DA. Cortical basket cell dysfunction in schizophrenia. J Physiol 2012; 590: 715-24.
39. Hasan A, Wobrock T, Grefkes C, et al. Deficient Inhibitory Cortical Networks in Antipsychotic-Naive Subjects at Risk of Developing First-Episode Psychosis and First-Episode Schizophrenia Patients: A Cross-Sectional Study. Biol Psychiatry 2012.
40. Yoon JH, Maddock RJ, Rokem A, et al. GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression. J Neurosci 2010; 30: 3777-81.
41. Goto N, Yoshimura R, Moriya J, et al. Reduction of brain gammaaminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T Proton MRS study. Schizophr Res 2009; 112: 192-3.
42. Tayoshi S, Nakataki M, Sumitani S, et al. GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study. Schizophr Res 2010; 117: 83-91.
43. Marsman A, van den Heuvel MP, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE. Glutamate in Schizophrenia: A Focused Review and Meta-Analysis of 1H-MRS Studies. Schizophr Bull 2011.
44. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 2000; 48: 381-8.
45. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 2001; 158: 918-25.
46. Raedler TJ, Knable MB, Jones DW, et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 2003; 160: 118-27.
47. Sarter M, Lustig C, Taylor SF. Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments. Neuropharmacology 2012; 62: 1544-53.
48. Balu DT, Coyle JT. Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neurosci Biobehav Rev 2011; 35: 848-70.
49. Kvajo M, McKellar H, Gogos JA. Molecules, signaling, and schizophrenia. Curr Top Behav Neurosci 2010; 4: 629-56.
50. St Clair D, Blackwood D, Muir W, et al. Association within a family of a balanced autosomal translocation with major mental illness. Lancet 1990; 336: 13-6.
51. Chen QY, Chen Q, Feng GY, et al. Case-control association study of Disrupted-in-Schizophrenia-1 (DISC1) gene and schizophrenia in the Chinese population. J Psychiatr Res 2007; 41: 428-34.
52. Ekelund J, Hennah W, Hiekkalinna T, et al. Replication of 1q42 linkage in Finnish schizophrenia pedigrees. Mol Psychiatry 2004; 9: 1037-41.
53. Mathieson I, Munafo MR, Flint J. Meta-analysis indicates that common variants at the DISC1 locus are not associated with schizophrenia. Mol Psychiatry 2011.
54. Chubb JE, Bradshaw NJ, Soares DC, Porteous DJ, Millar JK. The DISC locus in psychiatric illness. Mol Psychiatry 2008; 13: 36-64.
55. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 2000; 26: 119-36.
56. Calkins ME, Dobie DJ, Cadenhead KS, et al. The Consortium on the Genetics of Endophenotypes in Schizophrenia: model recruitment, assessment, and endophenotyping methods for a multisite collaboration. Schizophr Bull 2007; 33: 33-48.
57. Gur RE, Calkins ME, Gur RC, et al. The Consortium on the Genetics of Schizophrenia: neurocognitive endophenotypes. Schizophr Bull 2007; 33: 49-68.
58. Nuechterlein KH, Luck SJ, Lustig C, Sarter M. CNTRICS final task selection: control of attention. Schizophr Bull 2009; 35: 182-96.
59. Mass R, Wolf K, Wagner M, Haasen C. Differential sustained attention/vigilance changes over time in schizophrenics and controls during a degraded stimulus Continuous Performance Test. Eur Arch Psychiatry Clin Neurosci 2000; 250: 24-30.
60. Bergida H, Lenzenweger MF. Schizotypy and sustained attention: confirming evidence from an adult community sample. J Abnorm Psychol 2006; 115: 545-51.
61. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998; 12: 426-45.
62. Snitz BE, Macdonald AW, 3rd, Carter CS. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a metaanalytic review of putative endophenotypes. Schizophr Bull 2006; 32: 179-94.
63. Nuechterlein KH. Signal detection in vigilance tasks and behavioral attributes among offspring of schizophrenic mothers and among hyperactive children. J Abnorm Psychol 1983; 92: 4-28.
64. Cornblatt B, Obuchowski M, Roberts S, Pollack S, Erlenmeyer-Kimling L. Cognitive and behavioral precursors of schizophrenia. Dev Psychopathol 1999; 11: 487-508.
65. Aleman A, Hijman R, de Haan EH, Kahn RS. Memory impairment in schizophrenia: a meta-analysis. Am J Psychiatry 1999; 156: 1358-66.
66. Brazo P, Delamillieure P, Morello R, Halbecq I, Marie RM, Dollfus S. Impairments of executive/attentional functions in schizophrenia with primary and secondary negative symptoms. Psychiatry Res 2005; 133: 45-55.
67. Quinones RM, Calderin YC, Dominguez M, et al. Heritability of Trail Making Test performance in multiplex schizophrenia families: implications for the search for an endophenotype. Eur Arch Psychiatry Clin Neurosci 2009; 259: 475-81.
68. Thompson JL, Watson JR, Steinhauer SR, Goldstein G, Pogue-Geile MF. Indicators of genetic liability to schizophrenia: a sibling study of neuropsychological performance. Schizophr Bull 2005; 31: 85-96.
69. Becker JT, Morris RG. Working memory(s). Brain Cogn 1999; 41: 1-8.
70. Horan WP, Braff DL, Nuechterlein KH, et al. Verbal working memory impairments in individuals with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia. Schizophr Res 2008; 103: 218-28.
71. Saperstein AM, Fuller RL, Avila MT, et al. Spatial working memory as a cognitive endophenotype of schizophrenia: assessing risk for pathophysiological dysfunction. Schizophr Bull 2006; 32: 498-506.
72. Toulopoulou T, Picchioni M, Rijsdijk F, et al. Substantial genetic overlap between neurocognition and schizophrenia: genetic modeling in twin samples. Arch Gen Psychiatry 2007; 64: 1348-55.
73. Gasperoni TL, Ekelund J, Huttunen M, et al. Genetic linkage and association between chromosome 1q and working memory function in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003; 116B: 8-16.
74. Gao WJ, Krimer LS, Goldman-Rakic PS. Presynaptic regulation of recurrent excitation by D1 receptors in prefrontal circuits. Proc Natl Acad Sci USA 2001; 98: 295-300.
75. Weinberger DR, Egan MF, Bertolino A, et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 2001; 50: 825-44.
76. Lee J, Park S. Working memory impairments in schizophrenia: a meta-analysis. J Abnorm Psychol 2005; 114: 599-611.
77. Trandafir A, Meary A, Schurhoff F, Leboyer M, Szoke A. Memory tests in first-degree adult relatives of schizophrenic patients: a meta-analysis. Schizophr Res 2006; 81: 217-26.
78. Erlenmeyer-Kimling L, Rock D, Roberts SA, et al. Attention, memory, and motor skills as childhood predictors of schizophreniarelated psychoses: the New York High-Risk Project. Am J Psychiatry 2000; 157: 1416-22.
79. Cirillo MA, Seidman LJ. Verbal declarative memory dysfunction in schizophrenia: from clinical assessment to genetics and brain mechanisms. Neuropsychol Rev 2003; 13: 43-77.
80. Sitskoorn MM, Aleman A, Ebisch SJ, Appels MC, Kahn RS. Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis. Schizophr Res 2004; 71: 285-95.
81. Savitz J, van der Merwe L, Stein DJ, Solms M, Ramesar R. Neuropsychological status of bipolar I disorder: impact of psychosis. Br J Psychiatry 2009; 194: 243-51.
82. Zihl J, Gron G, Brunnauer A. Cognitive deficits in schizophrenia and affective disorders: evidence for a final common pathway disorder. Acta Psychiatr Scand 1998; 97: 351-7.
83. Borgwardt SJ, McGuire PK, Aston J, et al. Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. Schizophr Res 2008; 106: 108-14.
84. Pantelis C, Yucel M, Bora E, et al. Neurobiological markers of illness onset in psychosis and schizophrenia: The search for a moving target. Neuropsychol Rev 2009; 19: 385-98.
85. Kawada R, Yoshizumi M, Hirao K, et al. Brain volume and dysexecutive behavior in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1255-60.
86. Takahashi T, Wood SJ, Yung AR, et al. Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis. Arch Gen Psychiatry 2009; 66: 366-76.
87. Ho BC, Andreasen NC, Nopoulos P, Arndt S, Magnotta V, Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry 2003; 60: 585-94.
88. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr Res 2001; 49: 1-52.
89. Gaser C, Nenadic I, Buchsbaum BR, Hazlett EA, Buchsbaum MS. Ventricular enlargement in schizophrenia related to volume reduction of the thalamus, striatum, and superior temporal cortex. Am J Psychiatry 2004; 161: 154-6.
90. McDonald C, Marshall N, Sham PC, et al. Regional brain morphometry in patients with schizophrenia or bipolar disorder and their unaffected relatives. Am J Psychiatry 2006; 163: 478-87.
91. Kempton MJ, Geddes JR, Ettinger U, Williams SC, Grasby PM. Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Arch Gen Psychiatry 2008; 65: 1017-32.
92. Allen AJ, Griss ME, Folley BS, Hawkins KA, Pearlson GD. Endophenotypes in schizophrenia: a selective review. Schizophr Res 2009; 109: 24-37.
93. Sun J, Maller JJ, Guo L, Fitzgerald PB. Superior temporal gyrus volume change in schizophrenia: a review on region of interest volumetric studies. Brain Res Rev 2009; 61: 14-32.
94. Kyriakopoulos M, Frangou S. Recent diffusion tensor imaging findings in early stages of schizophrenia. Curr Opin Psychiatry 2009; 22: 168-76.
95. McIntosh AM, Munoz Maniega S, Lymer GK, et al. White matter tractography in bipolar disorder and schizophrenia. Biol Psychiatry 2008; 64: 1088-92.
96. Ardekani BA, Tabesh A, Sevy S, Robinson DG, Bilder RM, Szeszko PR. Diffusion tensor imaging reliably differentiates patients with schizophrenia from healthy volunteers. Hum Brain Mapp 2011; 32: 1-9.
97. Nakamura M, McCarley RW, Kubicki M, et al. Fronto-temporal disconnectivity in schizotypal personality disorder: a diffusion tensor imaging study. Biol Psychiatry 2005; 58: 468-78.
98. Hao Y, Yan Q, Liu H, et al. Schizophrenia patients and their healthy siblings share disruption of white matter integrity in the left prefrontal cortex and the hippocampus but not the anterior cingulate cortex. Schizophr Res 2009; 114: 128-35.
99. Sexton CE, Mackay CE, Ebmeier KP. A systematic review of diffusion tensor imaging studies in affective disorders. Biol Psychiatry 2009; 66: 814-23.
100. Barch DM, Moore H, Nee DE, Manoach DS, Luck SJ. CNTRICS imaging biomarkers selection: Working memory. Schizophr Bull 2012; 38: 43-52.
101. Ragland JD, Cohen NJ, Cools R, Frank MJ, Hannula DE, Ranganath C. CNTRICS imaging biomarkers final task selection: Long-term memory and reinforcement learning. Schizophr Bull 2012; 38: 62-72.
102. Carter CS, Minzenberg M, West R, Macdonald A, 3rd. CNTRICS imaging biomarker selections: Executive control paradigms. Schizophr Bull 2012; 38: 34-42.
103. Kim DI, Manoach DS, Mathalon DH, et al. Dysregulation of working memory and default-mode networks in schizophrenia using independent component analysis, an fBIRN and MCIC study. Hum Brain Mapp 2009; 30: 3795-811.
104. Manoach DS, Gollub RL, Benson ES, et al. Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance. Biol Psychiatry 2000; 48: 99-109.
105. Barch DM, Carter CS, Braver TS, et al. Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. Arch Gen Psychiatry 2001; 58: 280-8.
106. Perlstein WM, Dixit NK, Carter CS, Noll DC, Cohen JD. Prefrontal cortex dysfunction mediates deficits in working memory and prepotent responding in schizophrenia. Biol Psychiatry 2003; 53: 25-38.
107. Hill K, Mann L, Laws KR, Stephenson CM, Nimmo-Smith I, McKenna PJ. Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies. Acta Psychiatr Scand 2004; 110: 243-56.
108. Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC. Metaanalysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiatry 2009; 66: 811-22.
109. Guller Y, Ferrarelli F, Shackman AJ, et al. Probing Thalamic Integrity in Schizophrenia Using Concurrent Transcranial Magnetic Stimulation and Functional Magnetic Resonance Imaging. Arch Gen Psychiatry 2012.
110. Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol Pharmacol 2010; 77: 317-26.
111. Potkin SG, Turner JA, Brown GG, et al. Working memory and DLPFC inefficiency in schizophrenia: the FBIRN study. Schizophr Bull 2009; 35: 19-31.
112. Winterer G, Weinberger DR. Genes, dopamine and cortical signalto-noise ratio in schizophrenia. Trends Neurosci 2004; 27: 683-90.
113. Callicott JH, Egan MF, Mattay VS, et al. Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am J Psychiatry 2003; 160: 709-19.
114. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc Natl Acad Sci USA 2001; 98: 676-82.
115. Raichle ME. Two views of brain function. Trends Cogn Sci 2010; 14: 180-90.
116. Hasenkamp W, James GA, Boshoven W, Duncan E. Altered engagement of attention and default networks during target detection in schizophrenia. Schizophr Res 2011; 125: 169-73.
117. Skudlarski P, Jagannathan K, Anderson K, et al. Brain connectivity is not only lower but different in schizophrenia: a combined anatomical and functional approach. Biol Psychiatry 2010; 68: 61-9.
118. Whitfield-Gabrieli S, Thermenos HW, Milanovic S, et al. Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proc Natl Acad Sci USA 2009; 106: 1279-84.
119. Broyd SJ, Demanuele C, Debener S, Helps SK, James CJ, Sonuga-Barke EJ. Default-mode brain dysfunction in mental disorders: a systematic review. Neurosci Biobehav Rev 2009; 33: 279-96.
120. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 2001; 156: 234-58.
121. Swerdlow NR, Geyer MA, Braff DL. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) 2001; 156: 194-215.
122. Braff DL, Light GA. The use of neurophysiological endophenotypes to understand the genetic basis of schizophrenia. Dialogues Clin Neurosci 2005; 7: 125-35.
123. Braff DL, Geyer MA, Light GA, et al. Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr Res 2001; 49: 171-8.
124. Anokhin AP, Heath AC, Myers E, Ralano A, Wood S. Genetic influences on prepulse inhibition of startle reflex in humans. Neurosci Lett 2003; 353: 45-8.
125. Braff DL. Prepulse inhibition of the startle reflex: a window on the brain in schizophrenia. Curr Top Behav Neurosci 2010; 4: 349-71.
126. Heekeren K, Neukirch A, Daumann J, et al. Prepulse inhibition of the startle reflex and its attentional modulation in the human Sketamine and N, N-dimethyltryptamine (DMT) models of psychosis. J Psychopharmacol 2007; 21: 312-20.
127. Arango C, Summerfelt A, Buchanan RW. Olanzapine effects on auditory sensory gating in schizophrenia. Am J Psychiatry 2003; 160: 2066-8.
128. Freedman R, Adler LE, Leonard S. Alternative phenotypes for the complex genetics of schizophrenia. Biol Psychiatry 1999; 45: 551-8.
129. Heinrichs RW. Meta-analysis and the science of schizophrenia: variant evidence or evidence of variants? Neurosci Biobehav Rev 2004; 28: 379-94.
130. de Wilde OM, Bour LJ, Dingemans PM, Koelman JH, Linszen DH. A meta-analysis of P50 studies in patients with schizophrenia and relatives: differences in methodology between research groups. Schizophr Res 2007; 97: 137-51.
131. Schulze KK, Hall MH, McDonald C, et al. P50 auditory evoked potential suppression in bipolar disorder patients with psychotic features and their unaffected relatives. Biol Psychiatry 2007; 62: 121-8.
132. Freedman R, Olincy A, Ross RG, et al. The genetics of sensory gating deficits in schizophrenia. Curr Psychiatry Rep 2003; 5: 155-61.
133. Bledowski C, Prvulovic D, Hoechstetter K, et al. Localizing P300 generators in visual target and distractor processing: a combined event-related potential and functional magnetic resonance imaging study. J Neurosci 2004; 24: 9353-60.
134. Polich J, Criado JR. Neuropsychology and neuropharmacology of P3a and P3b. Int J Psychophysiol 2006; 60: 172-85.
135. Bramon E, Rabe-Hesketh S, Sham P, Murray RM, Frangou S. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res 2004; 70: 315-29.
136. Salisbury DF, Voglmaier MM, Seidman LJ, McCarley RW. Topographic abnormalities of P3 in schizotypal personality disorder. Biol Psychiatry 1996; 40: 165-72.
137. Blackwood DH, St Clair DM, Muir WJ, Duffy JC. Auditory P300 and eye tracking dysfunction in schizophrenic pedigrees. Arch Gen Psychiatry 1991; 48: 899-909.
138. van Tricht MJ, Nieman DH, Koelman JH, et al. Reduced parietal P300 amplitude is associated with an increased risk for a first psychotic episode. Biol Psychiatry 2010; 68: 642-8.
139. Bramon E, McDonald C, Croft RJ, et al. Is the P300 wave an endophenotype for schizophrenia? A meta-analysis and a family study. Neuroimage 2005; 27: 960-8.
140. Bestelmeyer PE, Phillips LH, Crombie C, Benson P, St Clair D. The P300 as a possible endophenotype for schizophrenia and bipolar disorder: Evidence from twin and patient studies. Psychiatry Res 2009; 169: 212-9.
141. Bruder GE. P300 findings for depressive and anxiety disorders. Ann N Y Acad Sci 1992; 658: 205-22.
142. Maurage P, Philippot P, Verbanck P, et al. Is the P300 deficit in alcoholism associated with early visual impairments (P100, N170)? An oddball paradigm. Clin Neurophysiol 2007; 118: 633-44.
143. Calkins ME, Iacono WG. Eye movement dysfunction in schizophrenia: a heritable characteristic for enhancing phenotype definition. Am J Med Genet 2000; 97: 72-6.
144. Calkins ME, Iacono WG, Ones DS. Eye movement dysfunction in first-degree relatives of patients with schizophrenia: a metaanalytic evaluation of candidate endophenotypes. Brain Cogn 2008; 68: 436-61.
145. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull 2007; 33: 69-94.
146. Ettinger U, Picchioni M, Hall MH, et al. Antisaccade performance in monozygotic twins discordant for schizophrenia: the Maudsley twin study. Am J Psychiatry 2006; 163: 543-5.
147. Louchart-de la Chapelle S, Nkam I, Houy E, et al. A concordance study of three electrophysiological measures in schizophrenia. Am J Psychiatry 2005; 162: 466-74.
148. Calkins ME, Curtis CE, Iacono WG, Grove WM. Antisaccade performance is impaired in medically and psychiatrically healthy biological relatives of schizophrenia patients. Schizophr Res 2004; 71: 167-78.
149. Thaker GK, Ross DE, Cassady SL, Adami HM, Medoff DR, Sherr J. Saccadic eye movement abnormalities in relatives of patients with schizophrenia. Schizophr Res 2000; 45: 235-44.
150. Sweeney JA, Strojwas MH, Mann JJ, Thase ME. Prefrontal and cerebellar abnormalities in major depression: evidence from oculomotor studies. Biol Psychiatry 1998; 43: 584-94.
151. Tien AY, Ross DE, Pearlson G, Strauss ME. Eye movements and psychopathology in schizophrenia and bipolar disorder. J Nerv Ment Dis 1996; 184: 331-8.
152. Ross DE, Thaker GK, Buchanan RW, et al. Association of abnormal smooth pursuit eye movements with the deficit syndrome in schizophrenic patients. Am J Psychiatry 1996; 153: 1158-65.
153. Ross DE, Buchanan RW, Medoff D, Lahti AC, Thaker GK. Association between eye tracking disorder in schizophrenia and poor sensory integration. Am J Psychiatry 1998; 155: 1352-7.
154. Thaker GK, Ross DE, Cassady SL, et al. Smooth pursuit eye movements to extraretinal motion signals: deficits in relatives of patients with schizophrenia. Arch Gen Psychiatry 1998; 55: 830-6.
155. Hong LE, Tagamets M, Avila M, Wonodi I, Holcomb H, Thaker GK. Specific motion processing pathway deficit during eye tracking in schizophrenia: a performance-matched functional magnetic resonance imaging study. Biol Psychiatry 2005; 57: 726-32.
156. Kathmann N, Frodl-Bauch T, Hegerl U. Stability of the mismatch negativity under different stimulus and attention conditions. Clin Neurophysiol 1999; 110: 317-23.
157. Fischer C, Morlet D, Bouchet P, Luaute J, Jourdan C, Salord F. Mismatch negativity and late auditory evoked potentials in comatose patients. Clin Neurophysiol 1999; 110: 1601-10.
158. Michie PT. What has MMN revealed about the auditory system in schizophrenia? Int J Psychophysiol 2001; 42: 177-94.
159. Shelley AM, Ward PB, Catts SV, Michie PT, Andrews S, McConaghy N. Mismatch negativity: an index of a preattentive processing deficit in schizophrenia. Biol Psychiatry 1991; 30: 1059-62.
160. Umbricht D, Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res 2005; 76: 1-23.
161. Umbricht D, Koller R, Schmid L, et al. How specific are deficits in mismatch negativity generation to schizophrenia? Biol Psychiatry 2003; 53: 1120-31.
162. Oades RD, Dittmann-Balcar A, Zerbin D, Grzella I. Impaired attention-dependent augmentation of MMN in nonparanoid vs paranoid schizophrenic patients: a comparison with obsessivecompulsive disorder and healthy subjects. Biol Psychiatry 1997; 41: 1196-210.
163. van der Stelt O, Gunning WB, Snel J, Kok A. No electrocortical evidence of automatic mismatch dysfunction in children of alcoholics. Alcohol Clin Exp Res 1997; 21: 569-75.
164. Michie PT, Innes-Brown H, Todd J, Jablensky AV. Duration mismatch negativity in biological relatives of patients with schizophrenia spectrum disorders. Biol Psychiatry 2002; 52: 749-58.
165. Bar-Haim Y, Marshall PJ, Fox NA, Schorr EA, Gordon-Salant S. Mismatch negativity in socially withdrawn children. Biol Psychiatry 2003; 54: 17-24.
166. Umbricht DS, Bates JA, Lieberman JA, Kane JM, Javitt DC. Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia. Biol Psychiatry 2006; 59: 762-72.
167. Bramon E, Croft RJ, McDonald C, et al. Mismatch negativity in schizophrenia: a family study. Schizophr Res 2004; 67: 1-10.
168. Salisbury DF, Shenton ME, Griggs CB, Bonner-Jackson A, McCarley RW. Mismatch negativity in chronic schizophrenia and first-episode schizophrenia. Arch Gen Psychiatry 2002; 59: 686-94.
169. Uhlhaas PJ, Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci 2010; 11: 100-13.
170. Kwon JS, O'Donnell BF, Wallenstein GV, et al. Gamma frequency-range abnormalities to auditory stimulation in schizophrenia. Arch Gen Psychiatry 1999; 56: 1001-5.
171. Light GA, Hsu JL, Hsieh MH, et al. Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol Psychiatry 2006; 60: 1231-40.
172. Spencer KM, Salisbury DF, Shenton ME, McCarley RW. Gammaband auditory steady-state responses are impaired in first episode psychosis. Biol Psychiatry 2008; 64: 369-75.
173. Krishnan GP, Vohs JL, Hetrick WP, et al. Steady state visual evoked potential abnormalities in schizophrenia. Clin Neurophysiol 2005; 116: 614-24.
174. Hirano S, Hirano Y, Maekawa T, et al. Abnormal neural oscillatory activity to speech sounds in schizophrenia: a magnetoencephalography study. J Neurosci 2008; 28: 4897-903.
175. Roach BJ, Mathalon DH. Event-related EEG time-frequency analysis: an overview of measures and an analysis of early gamma band phase locking in schizophrenia. Schizophr Bull 2008; 34: 907-26.
176. Spencer KM, Nestor PG, Perlmutter R, et al. Neural synchrony indexes disordered perception and cognition in schizophrenia. Proc Natl Acad Sci USA 2004; 101: 17288-93.
177. Gallinat J, Winterer G, Herrmann CS, Senkowski D. Reduced oscillatory gamma-band responses in unmedicated schizophrenic patients indicate impaired frontal network processing. Clin Neurophysiol 2004; 115: 1863-74.
178. Spencer KM, Niznikiewicz MA, Shenton ME, McCarley RW. Sensory-evoked gamma oscillations in chronic schizophrenia. Biol Psychiatry 2008; 63: 744-7.
179. Cho RY, Konecky RO, Carter CS. Impairments in frontal cortical gamma synchrony and cognitive control in schizophrenia. Proc Natl Acad Sci USA 2006; 103: 19878-83.
180. Haenschel C, Bittner RA, Waltz J, et al. Cortical oscillatory activity is critical for working memory as revealed by deficits in early-onset schizophrenia. J Neurosci 2009; 29: 9481-9.
181. Minzenberg MJ, Firl AJ, Yoon JH, Gomes GC, Reinking C, Carter CS. Gamma oscillatory power is impaired during cognitive control independent of medication status in first-episode schizophrenia. Neuropsychopharmacology 2010; 35: 2590-9.
182. Spencer KM, Nestor PG, Niznikiewicz MA, Salisbury DF, Shenton ME, McCarley RW. Abnormal neural synchrony in schizophrenia. J Neurosci 2003; 23: 7407-11.
183. Uhlhaas PJ, Linden DE, Singer W, et al. Dysfunctional long-range coordination of neural activity during Gestalt perception in schizophrenia. J Neurosci 2006; 26: 8168-75.
184. Ferrarelli F, Massimini M, Peterson MJ, et al. Reduced evoked gamma oscillations in the frontal cortex in schizophrenia patients: a TMS/EEG study. Am J Psychiatry 2008; 165: 996-1005.
185. Ferrarelli F, Sarasso S, Guller Y, et al. Reduced Natural Oscillatory Frequency of Frontal Thalamocortical Circuits in Schizophrenia. Arch Gen Psychiatry 2012.
186. Ferrarelli F, Huber R, Peterson MJ, et al. Reduced sleep spindle activity in schizophrenia patients. Am J Psychiatry 2007; 164: 483-92.
187. Ferrarelli F, Peterson MJ, Sarasso S, et al. Thalamic dysfunction in schizophrenia suggested by whole-night deficits in slow and fast spindles. Am J Psychiatry 2010; 167: 1339-48.
188. Ferrarelli F, Tononi G. The thalamic reticular nucleus and schizophrenia. Schizophr Bull 2011; 37: 306-15.
189. Linkenkaer-Hansen K, Smit DJ, Barkil A, et al. Genetic contributions to long-range temporal correlations in ongoing oscillations. J Neurosci 2007; 27: 13882-9.
190. Hong LE, Summerfelt A, Mitchell BD, et al. Sensory gating endophenotype based on its neural oscillatory pattern and heritability estimate. Arch Gen Psychiatry 2008; 65: 1008-16.
191. an der Heiden W, Hafner H. The epidemiology of onset and course of schizophrenia. Eur Arch Psychiatry Clin Neurosci 2000; 250: 292-303.
192. Klosterkotter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 2001; 58: 158-64.
193. Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992; 149: 1183-8.
194. Gooding DC, Tallent KA, Matts CW. Rates of avoidant, schizotypal, schizoid and paranoid personality disorders in psychometric high-risk groups at 5-year follow-up. Schizophr Res 2007; 94: 373-4.
195. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581-9.
196. Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003; 290: 2693-702.
197. Javitt DC, Spencer KM, Thaker GK, Winterer G, Hajos M. Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov 2008; 7: 68-83.
198. Ishikawa M, Hashimoto K. alpha7 nicotinic acetylcholine receptor as a potential therapeutic target for schizophrenia. Curr Pharm Des 2011; 17: 121-9.
199. Durany N, Zochling R, Boissl KW, et al. Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. Neurosci Lett 2000; 287: 109-12.
200. Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT. Neurobiology of schizophrenia. Neuron 2006; 52: 139-53.
201. Fitzgerald PB. BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia. Curr Opin Investig Drugs 2010; 11: 92-100.
202. Tamminga CA. The neurobiology of cognition in schizophrenia. J Clin Psychiatry 2006; 67: e11.
203. Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006; 63: 630-8.
204. Freedman R, Olincy A, Buchanan RW, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008; 165: 1040-7.
205. Shekhar A, Potter WZ, Lightfoot J, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 2008; 165: 1033-9.
206. Friedman JI, Carpenter D, Lu J, et al. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J Clin Psychopharmacol 2008; 28: 59-63.
207. Kelly DL, Buchanan RW, Boggs DL, et al. A randomized doubleblind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry 2009; 70: 518-25.
208. Schneider JS, Tinker JP, Van Velson M, Giardiniere M. Effects of the partial glycine agonist D-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys. Brain Res 2000; 860: 190-4.
209. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001; 25: 455-67.
210. Tsai GE, Lin PY. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des 2010; 16: 522-37.
211. Hashimoto K. Glycine transporter-1: a new potential therapeutic target for schizophrenia. Curr Pharm Des 2011; 17: 112-20.
212. de Bartolomeis A, Sarappa C, Magara S, Iasevoli F. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia. Eur J Pharmacol 2012; 682: 1-11.
213. Ayalew M, Le-Niculescu H, Levey DF, et al. Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol Psychiatry 2012.
214. Price GW, Michie PT, Johnston J, et al. A multivariate electrophysiological endophenotype, from a unitary cohort, shows greater research utility than any single feature in the Western Australian family study of schizophrenia. Biol Psychiatry 2006; 60: 1-10.
215. Oertel-Knochel V, Bittner RA, Knochel C, Prvulovic D, Hampel H. Discovery and development of integrative biological markers for schizophrenia. Prog Neurobiol 2011; 95: 686-702.
216. Pearlson GD, Folley BS. Schizophrenia, psychiatric genetics, and Darwinian psychiatry: an evolutionary framework. Schizophr Bull 2008; 34: 722-33.